目的 观察血必净注射液联合人免疫球蛋白治疗重症病毒性肺炎的临床疗效。方法 选取2012年1月-2015年12月在南京市第一医院住院治疗的重症病毒性肺炎患者92例，随机分为对照组和治疗组，每组各46例。对照组患者静脉注射静注人免疫球蛋白（pH 4），10 g/次，1次/d；治疗组在对照组的基础上静脉注射血必净注射液，50 mL/次，2次/d。两组患者均连续治疗7 d。治疗后，比较两组患者临床疗效、临床症状体征改善及高敏C反应蛋白（hs-CRP）、白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）的水平改变。结果 治疗后，对照组和治疗组的总有效率分别为82.61%和91.30%，两组总有效率比较差异有统计学意义（P<0.05）。治疗后，治疗组患者退热时间、咳嗽和气喘消退时间明显短于对照组，两组临床症状体征改善情况比较差异有统计学意义（P<0.05）。治疗后，两组患者hs-CRP、IL-6、TNF-α水平均明显降低，同组治疗前后比较具有统计学意义（P<0.05）；且治疗组上述炎症因子降低程度更明显，两组比较差异具有统计学意义（P<0.05）。结论 血必净注射液联合人免疫球蛋白治疗重症病毒性肺炎临床疗效显著，能有效改善患者的症状体征和炎症因子，具有一定的临床推广应用价值。

Objective To observe the clinical curative effect of Xuebijing Injection combined with human immunoglobulin in treatment of severe viral pneumonia. Methods Patients (92 cases) with severe viral pneumonia in Nanjing First Hospital from January 2012 to December 2015 were randomly divided into control and treatment groups, and each group had 46 cases. The patients in the control group were iv administered with Human Immunoglobulin (pH 4) for iv injection, 10 g/time, once daily. The patients in the treatment group were iv administered with Xuebijing Injection on the basis of the control group, 50 mL/time, twice daily. The patients in two groups were treated for 7 d. After treatment, the efficacy and the clinical symptoms and signs were evaluated, and hs-CRP, IL-6, and TNF-α in two groups were compared. Results After treatment, the efficacies in the control and treatment groups were 82.61% and 91.30%, respectively, and there were differences between two groups (P<0.05). After treatment, antifebrile time, cough and asthma disappeared time in the treatment group were significantly shorter than those in the control group, with significant differences between two groups (P<0.05). And after treatment, the levels of hs-CRP, IL-6, and TNF-α in two groups were significantly decreased, and the differences were statistically significant in the same group (P<0.05). And the decrease degree of those inflammatory factors in the treatment group was more significant than that in the control group, with significant differences between two groups (P<0.05). Conclusion Xuebijing Injection combined with human immunoglobulin has a significant clinical curative effect in treatment of severe viral pneumonia, can effectively improve the symptoms and signs and inflammatory factors, which has a certain clinical application value.